Cancer Family
Malignant Breast Neoplasm
CI-CAN-00000227Explore in graph →
Top-level2,627 active trials43 approved drugs310 evidence items
- NCIt
- C9335
- ICD-10
- C50
- DOID
- 1612
- Other
- 2 more codes
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000227Explore in graph →
Clinical trials
12,355 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,367)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06145399 | A Study of 1 8F-FDHT PET/MRIScans in Women With Breast Cancer | withdrawn | Early Phase 1 | 0 | Memorial Sloan Kettering Cancer CenterOTHER | 0 | May 18, 2025 | clinicaltrials |
| NCT06756295 | A Phase I/ II Study of Fragmented Autoantigen Stimulated T-cell-immunotherapy Combined with Radiotherapy (FAST-CR)(FAST-CR) | not yet recruiting | Early Phase 1 | 154 | Fengming KongOTHER | 0 | Mar 12, 2025 |
| NCT06760429 | Comparative Evaluation of Pectoral Nerve Block Type II Versus Rhomboid Intercostal and Subserratus Plane Block in Breast Cancer Mastectomy for Postoperative Analgesia: a Randomized, Controlled Trial | completed | Early Phase 1 | 60 | Inner Mongolia Baogang HospitalOTHER | 1 | Jan 6, 2025 | clinicaltrials |
| NCT03473691 | Pilot Study of Glembatumumab Vedotin Following Doxorubicin and Cytoxan as Neo-adjuvant Therapy in Gp-NMB-expressing High Risk Triple Negative Breast Cancer(Breast50) | withdrawn | Early Phase 1 | 0 | University of VirginiaOTHER | 0 | Dec 9, 2024 | clinicaltrials |
| NCT04674722 | HER2 Expression Detection and Radionuclide Therapy in Breast Cancer Using 99mTc/188Re Labeled Single Domain Antibody | completed | Early Phase 1 | 43 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | Dec 9, 2024 | clinicaltrials |
| NCT03514121 | FPA150 in Patients With Advanced Solid Tumors(FPA150-001) | terminated | Early Phase 1 | 95 | Five Prime Therapeutics, Inc.INDUSTRY | 2 | Nov 22, 2024 | clinicaltrials |
| NCT03911453 | Window of Opportunity Trial, PARP Inhibitor Rucaparib Affect on PD-L1 Expression in Triple Negative Breast Tumors | completed | Early Phase 1 | 20 | University of ArizonaOTHER | 1 | Oct 3, 2024 | clinicaltrials |
| NCT04481230 | Assessment of 99mTc-NTP 15-5 Uptake on Cartilage, a New Proteoglycan Tracer(CARSPECT) | completed | Early Phase 1 | 6 | Centre Jean PerrinOTHER | 1 | Oct 1, 2024 | clinicaltrials |
| NCT02913430 | Treatment of Metastatic Breast Cancer With Fulvestrant Plus Palbociclib or Tamoxifen Plus Palbociclib | completed | Early Phase 1 | 7 | Shannon PuhallaOTHER | 1 | Sep 23, 2024 | clinicaltrials |
| NCT05672342 | Phytocannabinoids for the Treatment of Chronic Chemotherapy-Induced Peripheral Neuropathy in Breast and Colon Cancer Survivors | withdrawn | Early Phase 1 | 0 | City of Hope Medical CenterOTHER | 1 | Aug 9, 2024 | clinicaltrials |
| NCT02415387 | Typhoid Vaccine in Testing Response to Immune Stress in Patients With Stage I-IIIA Breast Cancer(IMPACT) | completed | Early Phase 1 | 172 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Jul 24, 2024 | clinicaltrials |
| NCT05549024 | 68Ga-RM26-RGD PET/CT Imaging in the GRPR and αvβ3 Positive Tumor Patients | recruiting | Early Phase 1 | 90 | Peking Union Medical College HospitalOTHER | 1 | Jul 5, 2024 | clinicaltrials |
| NCT03542695 | 64 Cu-DOTA-alendronate PET Imaging in Localizing and Characterizing Breast Calcifications in Participants Before Undergoing Mastectomy | completed | Early Phase 1 | 1 | City of Hope Medical CenterOTHER | 1 | Jun 24, 2024 | clinicaltrials |
| NCT04925817 | 3D Ultrasound Microvessel Imaging for Breast Masses | completed | Early Phase 1 | 50 | Mayo ClinicOTHER | 1 | Jun 7, 2024 | clinicaltrials |
| NCT04752267 | 18F-FMAU PET/CT and MRI for the Detection of Brain Tumors in Patients With Brain Cancer or Brain Metastases | completed | Early Phase 1 | 10 | University of Southern CaliforniaOTHER | 1 | May 24, 2024 | clinicaltrials |
| NCT06090630 | MR Correlated Spectroscopic Imaging for Diagnosing Breast Cancer | completed | Early Phase 1 | 83 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Apr 17, 2024 | clinicaltrials |
| NCT06361264 | Clinical Study of Personalized Chemotherapy for Breast Cancer With Low Doses of Cyclophosphamide | unknown | Early Phase 1 | 20 | KARANAHANOTHER | 1 | Apr 11, 2024 | clinicaltrials |
| NCT01916122 | Fluorestradiol (FES) PET/CT for Imaging Estrogen Receptor Status | completed | Early Phase 1 | 54 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 5, 2024 | clinicaltrials |
| NCT03361800 | Window of Opportunity Trial of Entinostat in Patients With Newly Diagnosed Stage I-IIIC,TNBC | terminated | Early Phase 1 | 5 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Mar 25, 2024 | clinicaltrials |
| NCT03564782 | Examining Bioactivity of PVSRIPO in Invasive Breast Cancer | completed | Early Phase 1 | 5 | Istari Oncology, Inc.INDUSTRY | 1 | Feb 8, 2024 | clinicaltrials |
| NCT05238831 | SMMART Adaptive Clinical Treatment (ACT) Trial | withdrawn | Early Phase 1 | 0 | OHSU Knight Cancer InstituteOTHER | 0 | Jan 23, 2024 | clinicaltrials |
| NCT01383135 | Biodistribution and Safety of the PET Probes [18F]FPRGD2 and [18F]FPPRGD2 | completed | Early Phase 1 | 27 | Stanford UniversityOTHER | 1 | Jan 12, 2024 | clinicaltrials |
| NCT05465590 | A Phase 1 Study to Evaluate Paclitaxel Conjugated CXC Receptor 4 Antagonist (MB1707) in Patients With Advanced Cancer | withdrawn | Early Phase 1 | 0 | Mainline Biosciences, Inc.INDUSTRY | 0 | Dec 21, 2023 | clinicaltrials |
| NCT03928210 | Digoxin Induced Dissolution of CTC Clusters | completed | Early Phase 1 | 58 | University Hospital, Basel, SwitzerlandOTHER | 1 | Dec 13, 2023 | clinicaltrials |
| NCT04341129 | Abbreviated MRI Protocol: Initial Experience With Dotarem® (Gadoterate Meglumine) | completed | Early Phase 1 | 50 | University of ChicagoOTHER | 1 | Dec 5, 2023 | clinicaltrials |
| NCT05436808 | Partial Chest Wall Radiation Therapy After Surgery for Lymph Node Negative Breast Cancer | withdrawn | Early Phase 1 | 0 | Stony Brook UniversityOTHER | 1 | Oct 18, 2023 | clinicaltrials |
| NCT01074814 | Pilot Study Using Molecular Profiling to Find Potential Targets & Select Treatments for Pts With Met br ca(Side-Out) | completed | Early Phase 1 | 28 | Translational Drug DevelopmentOTHER | 1 | Sep 28, 2023 | clinicaltrials |
| NCT01980823 | Pre-Surgical Trial of the Combination of Metformin and Atorvastatin in Newly Diagnosed Operable Breast Cancer | completed | Early Phase 1 | 23 | Columbia UniversityOTHER | 1 | Aug 30, 2023 | clinicaltrials |
| NCT05961111 | A Clinical Study on Oncolytic Virus Injection (R130 OV) for the Treatment of Advanced Solid Tumors | unknown | Early Phase 1 | 20 | Shanghai Yunying Medical TechnologyINDUSTRY | 1 | Jul 27, 2023 | clinicaltrials |
| NCT03599453 | Chemokine Modulation Therapy and Pembrolizumab in Treating Participants With Metastatic Triple-Negative Breast Cancer | completed | Early Phase 1 | 8 | Roswell Park Cancer InstituteOTHER | 1 | Jul 18, 2023 | clinicaltrials |
| NCT02538484 | Impact of Omega 3 Fatty Acid Supplementation on Aromatase in Obese Subjects | completed | Early Phase 1 | 24 | The University of Texas Health Science Center at San AntonioOTHER | 1 | Jul 17, 2023 | clinicaltrials |
| NCT03122444 | Imipramine on ER+ve and Triple Negative Breast Cancer | completed | Early Phase 1 | 17 | The University of Texas Health Science Center at San AntonioOTHER | 1 | Jun 28, 2023 | clinicaltrials |
| NCT04610528 | A Window-of-opportunity Study of U3-1402, a HER3-targeting Antibody-drug Conjugate in Operable Breast Cancer According to ERBB3 Expression(TOT-HER3) | unknown | Early Phase 1 | 80 | SOLTI Breast Cancer Research GroupOTHER | 1 | Jun 23, 2023 | clinicaltrials |
| NCT03060356 | Autologous T Cells Expressing MET scFv CAR (RNA CART-cMET) | terminated | Early Phase 1 | 77 | University of PennsylvaniaOTHER | 1 | Jun 22, 2023 | clinicaltrials |
| NCT05886075 | A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Relapsed/Refractory Advanced Solid Tumors | unknown | Early Phase 1 | 24 | Shanghai Yunying Medical TechnologyINDUSTRY | 1 | Jun 2, 2023 | clinicaltrials |
| NCT05860374 | A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Advanced Solid Tumors | unknown | Early Phase 1 | 20 | Shanghai Yunying Medical TechnologyINDUSTRY | 1 | May 16, 2023 | clinicaltrials |
| NCT05368506 | ZN-c3 for the Treatment of Metastatic Triple-Negative Breast Cancer and Advanced Ovarian Cancer | withdrawn | Early Phase 1 | 0 | OHSU Knight Cancer InstituteOTHER | 0 | May 6, 2023 | clinicaltrials |
| NCT05828238 | Positron Emission Tomograph(PET) Imaging Explores the Role of SF-DEVD-2 in Monitoring Tumor Efficacy | unknown | Early Phase 1 | 10 | Affiliated Hospital of Jiangnan UniversityOTHER | 1 | Apr 25, 2023 | clinicaltrials |
| NCT04857697 | Effects of Probiotics on the Gut Microbiome and Immune System in Operable Stage I-III Breast or Lung Cancer | completed | Early Phase 1 | 6 | Mayo ClinicOTHER | 1 | Apr 21, 2023 | clinicaltrials |
| NCT04040686 | HER2 Expression Detection in Breast Cancer Using 99mTc-NM-02 | completed | Early Phase 1 | 10 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | Apr 14, 2023 | clinicaltrials |
| NCT04041128 | PARP Inhibition During Pre-surgical Window in Breast/Ovary Cancer | completed | Early Phase 1 | 14 | University of Texas Southwestern Medical CenterOTHER | 1 | Mar 20, 2023 | clinicaltrials |
| NCT05753657 | A Pilot Study of Monitoring Insulin Levels and Treating Hyperinsulinemia and Hyperglycemia With Pioglitazone in Patients Treated With Alpelisib for Metastatic Breast Cancer. | recruiting | Early Phase 1 | 30 | Rambam Health Care CampusOTHER | 1 | Mar 3, 2023 | clinicaltrials |
| NCT03411070 | SCOUT Reflector for Tagging Lymph Nodes for Targeted Removal in Patients With Breast Cancer | completed | Early Phase 1 | 27 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jan 17, 2023 | clinicaltrials |
| NCT05686720 | Single-arm, Open-label Clinical Study of SZ011 in the Treatment of Advanced Triple Negative Breast Cancer | unknown | Early Phase 1 | 12 | First Affiliated Hospital of Shantou University Medical CollegeOTHER | 1 | Jan 17, 2023 | clinicaltrials |
| NCT05680662 | The Study of Quadruple Therapy Quercetin, Zinc, Metformin, and EGCG as Adjuvant Therapy for Early, Metastatic Breast Cancer and Triple-negative Breast Cancer, a Novel Mechanism | unknown | Early Phase 1 | 200 | Ministry of Health, Saudi ArabiaOTHER_GOV | 0 | Jan 11, 2023 | clinicaltrials |
| NCT04249167 | Cryoablation, Atezolizumab/Nab-paclitaxel for Locally Advanced or Metastatic Triple Negative Breast Cancer | withdrawn | Early Phase 1 | 0 | Mayo ClinicOTHER | 0 | Jan 6, 2023 | clinicaltrials |
| NCT03407716 | Ginseng in Decreasing Cancer-Related Fatigue After Treatment in Cancer Survivors | completed | Early Phase 1 | 2 | Mayo ClinicOTHER | 1 | Jan 5, 2023 | clinicaltrials |
| NCT02013492 | Propranolol Hydrochloride in Treating Patients With Locally Recurrent or Metastatic Solid Tumors That Cannot Be Removed By Surgery | completed | Early Phase 1 | 1 | William CarsonOTHER | 1 | Dec 6, 2022 | clinicaltrials |
| NCT05622240 | 99mTc-MIRC213 SPECT/CT for the Detection of HER2-positive Breast Cancer | unknown | Early Phase 1 | 30 | Peking Union Medical College HospitalOTHER | 1 | Nov 21, 2022 | clinicaltrials |
| NCT04797728 | Elacestrant in Preoperative Setting, a Window of Opportunity Study(ELIPSE) | completed | Early Phase 1 | 23 | SOLTI Breast Cancer Research GroupOTHER | 1 | Oct 26, 2022 | clinicaltrials |
Data updated 22 days agoSource updated May 18, 2025source: clinicaltrials